Abstract
Parkinson’s disease (PD) is, after Alzheimer’s disease, the second most common neurodegenerative disorder with an approximate prevalence of 0.5–1 % among persons 65–69 years of age, rising to 1–3 % among persons 80 years of age and older. Pathologically, PD is characterized by the loss of neurons in the substantia nigra pars compacta (SNpc), and by the presence of eosinophilic protein deposits (Lewy bodies) in this region, in other aminergic nuclei and in cortical and limbic structures. Moreover, it has now been shown that pathology also involves the peripheral nervous system. Braak and colleagues suggested a thread of pathology starting from the vagal nerve to progress to the brainstem, and eventually to limbic and neocortical brain regions. This progression of pathology may account for the clinical evolution of PD toward a composite symptomatology. However, this hypothesis has been criticized by others. In this chapter, we review the clinical features of PD (motor and nonmotor) and their pathological correlates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarsland D, Pahlhagen S, Ballard CG, Ehrt U, Svenningsson P (2012) Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol 8(1):35–47
Alegre M, López-Azcárate J, Alonso-Frech F, Rodríguez-Oroz MC, Valencia M, Guridi J, Artieda J, Obeso JA (2012) Subthalamic activity during diphasic dyskinesias in Parkinson’s disease. Mov Disord 27:1178–1181
Alonso-Frech F, Zamarbide I, Alegre M, Rodríguez-Oroz MC, Guridi J, Manrique M, Valencia M, Artieda J, Obeso JA (2006) Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson’s disease. Brain 129:1748–1757
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al, PRIAMO study group (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24(11):1641–1649
Beavan MS, Schapira AH (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann Med 45(8):511–521
Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V et al (2013) EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 20(1):16–34
Bohnen NI, Albin RL (2009) Cholinergic denervation occurs early in Parkinson disease. Neurology 73:256–257
Bonifati V (2012) Autosomal recessive Parkinsonism. Parkinsonism Relat Disord 18(Suppl 1):S4–S6
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211
Brooks DJ, Pavese N (2011) Imaging biomarkers in Parkinson’s disease. Prog Neurobiol 95(4):614–628
Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 64(5):485–491
Cenci MA, Lundblad M (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99(2):381–392
Cenci MA, Ohlin KE, Odin P (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson’s disease. CNS Neurol Disord Drug Targets 10(6):670–684
Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T (2011) Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain 134:1493–1505
Derkinderen P, Rouaud T, Lebouvier T, Bruley des Varannes S, Neunlist M, De Giorgio R (2011) Parkinson disease: the enteric nervous system spills its guts. Neurology 77(19):1761–1767
Diederich NJ, McIntyre DJ (2012) Sleep disorders in Parkinson’s disease: many causes, few therapeutic options. J Neurol Sci 314(1–2):12–19
Donaldson I, Marsden CD, Schneider S, Bhatia K (2012) Marsden’s book of movement disorders. Oxford University Press, Oxford
Dorsey ER, Constantinescu R, Thompson JP, Biglan K, Holloway RG, Kieburtz K, Marshall FJ, Ravina B, Schifitto G, Siderowf A, Tanner C (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386
Doty RL (2012) Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis 46(3):527–552
Edwards LL, Quigley EM, Pfeiffer RF (1992) Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology 42(4):726–732
Fearnley JM, Lees AJ (1991) Ageing Parkinson’s disease: Substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301
Frisina PG, Haroutunian V, Libow LS (2009) The neuropathological basis for depression in Parkinson’s disease. Parkinsonism Relat Disord 15(2):144–148
Garcia-Borreguero D, Larrosa O, Bravo M (2003) Parkinson’s disease and sleep. Sleep Med Rev 7(2):115–129
Gasser T (2010) Identifying PD-causing genes and genetic susceptibility factors: current approaches and future prospects. Prog Brain Res 183:3–20
Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol 14:523–528
Halliday G, McCann H, Shepherd C (2012) Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother 12(6):673–686
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844
Jellinger KA (2012) Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 27(1):8–30
Kashihara K, Hanaoka A, Imamura T (2011) Frequency and characteristics of taste impairment in patients with Parkinson’s disease: results of a clinical interview. Int Med 50(20):2311–2315
Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol 17(4):417–423
Kim HJ, Jeon BS, Lee JY, Cho YJ, Hong KS, Cho JY (2011) Taste function in patients with Parkinson disease. J Neurol 258(6):1076–1079
Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136:2419–2431
Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(9680):2055–2066
Lewis SJ, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348
Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I et al (2003) Movement disorders society scientific issues committee. Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18(5):467–486
Löhle M, Storch A, Reichmann H (2009) Beyond tremor and rigidity: non-motor features of Parkinson’s disease. J Neural Transm 116(11):1483–1492
Lozano AM (2000) Neuronal recordings in Parkinson’s disease patients with dyskinesias induced by apomorphine. Ann Neurol 47(1):141–146
Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8(12):1158–1171
Manson A, Stirpe P, Schrag A (2012) Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2(3):189–198
Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, MacPhee G, Brown RG, Naidu Y, Clayton L, Abe K, Tsuboi Y, MacMahon D, Barone P, Rabey M, Bonuccelli U, Forbes A, Breen K, Tluk S, Olanow CW, Thomas S, Rye D, Hand A, Williams AJ, Ondo W, Chaudhuri KR (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22(11):1623–1629
Nobrega AC, Rodrigues B, Torres AC, Scarpel RD, Neves CA, Melo A (2008) Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease? Parkinsonism Relat Disord 14(3):243–245
Obeso JA, Rodríguez-Oroz MC, Rodríguez M, Arbizu J, Giménez-Amaya JM (2002) The basal ganglia and disorders of movement: pathophysiological mechanisms. News Physiol Sci 17:51–55
Olanow WC, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) Investigators (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071
Ondo (2011) Motor complications in Parkinson’s disease. Int J Neurosci 121:37–44
Pagonabarraga J, Kulisevsky J (2012) Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis 46(3):590–596
Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O’Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2:898
Paulus W, Jellinger K (1991) The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50(6):743–755
Poewe W (2009) Clinical measures of progression in Parkinson’s disease. Mov Disord 24(2):S671–S676
Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P (2010) Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 75(21):1920–1927
Postuma RB (2014) Prodromal Parkinson’s disease–using REM sleep behavior disorder as a window. Parkinsonism Relat Disord 20(Suppl 1):S1–S4
Pouclet H, Lebouvier T, Coron E, des Varannes SB, Rouaud T, Roy M, Neunlist M, Derkinderen P (2012) A comparison between rectal and colonic biopsies to detect Lewy pathology in Parkinson’s disease. Neurobiol Dis. 45(1):305–309
Raggi A, Bella R, Pennisi G, Neri W, Ferri R (2013) Sleep disorders in Parkinson’s disease: a narrative review of the literature. Rev Neurosci 24(3):279–291
Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322
Roos RA, Jongen JC, van der Velde EA (1996) Clinical course of patients with idiopathic Parkinson’s disease. Mov Disord 11(3):236–242
Sakakibara R, Uchiyama T, Yamanishi T, Kishi M (2010) Genitourinary dysfunction in Parkinson’s disease. Mov Disord 25(1):2–12
Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N et al, Juntendo Parkinson Study Group (2006) Prognosis of Parkinson’s disease: time to stage III, IV, V, and to motor fluctuations. Mov Disord 21(9):1384–1395
Schneider SA, Alexoudi A, Böttner M, et al Can we use peripheral tissue biopsies to diagnose Parkinson´s disease? A review of the literature (in preparation)
Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132:2947–2957
Shah M, Deeb J, Fernando M, Noyce A, Visentin E, Findley LJ, Hawkes CH (2009) Abnormality of taste and smell in Parkinson’s disease. Parkinsonism Relat Disord 15(3):232–237
Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases.Mov Disord 27(6):716–719
Sidransky E, Lopez G (2012) The link between the GBA gene and parkinsonism. Lancet Neurol 11(11):986–998
Stamey W, Davidson A, Jankovic J (2008) Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol 14(4):253–254
Surmeier DJ, Schumacker PT (2013) Calcium, bioenergetics, and neuronal vulnerability in Parkinson’s disease. J Biol Chem 288(15):10736–10741
Svenningsson P, Westman E, Ballard C, Aarsland D (2012) Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11(8):697–707
Thanvi B, Lo N, Robinson T (2007) Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 83(980):384–388
Truong DD, Wolters EC (2009) Recognition and management of Parkinson’s disease during the premotor (prodromal) phase. Expert Rev Neurother 9(6):847–857
van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J (2010) The identification of Parkinson’s disease subtypes using cluster analysis: a systematic review. Mov Disord 25(8):969–978
Vilas D, Pont-Sunyer C, Tolosa E (2012) Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S80–S84
Visanji NP, Brooks PL, Hazrati LN, Lang AE (2013) The prion hypothesis in Parkinson's disease: braak to the future. Acta Neuropathol Commun 1(1):2
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E (2009) Chronic dopaminergic stimulation in Parkinson’s disease: from dyskinesias to impulse control disorders. Lancet Neurol 8:1140–1149
Winge K, Fowler CJ (2006) Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 21(6):737–745
Wolters ECh (2009) Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord 15(Suppl 3):S6–S12
Wolters ECh, Braak H (2006) Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl 70:309–319
Schneider SA, Alexoudi A, Boettner M, Deuschl G, Wedel T (in prep) Can we use peripheral tissue biopsies to diagnose Parkinson´s disease? A review of the literature
Yeo L, Singh R, Gundeti M, Barua JM, Masood J (2012) Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol 44(2):415–424
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schneider, S.A., Obeso, J.A. (2014). Clinical and Pathological Features of Parkinson’s Disease. In: Nguyen, H., Cenci, M. (eds) Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. Current Topics in Behavioral Neurosciences, vol 22. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_317
Download citation
DOI: https://doi.org/10.1007/7854_2014_317
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46343-7
Online ISBN: 978-3-662-46344-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)